[F-18]-Fludeoxyglucose — Competitive Intelligence Brief

[F-18]-Fludeoxyglucose ([F-18]-Fludeoxyglucose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; PET imaging agent. Area: Oncology; Neurology; Cardiology.

marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase Oncology; Neurology; Cardiology Small molecule

Target snapshot

[F-18]-Fludeoxyglucose ([F-18]-Fludeoxyglucose) — University of Saskatchewan. [F-18]-Fludeoxyglucose is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues, enabling visualization of glucose uptake via positron emission tomography (PET) imaging.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
[F-18]-Fludeoxyglucose TARGET	[F-18]-Fludeoxyglucose	University of Saskatchewan	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	Vanderbilt-Ingram Cancer Center	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)
Dexamethasone plus Radium-223	Dexamethasone plus Radium-223	University Health Network, Toronto	marketed	Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical	Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor
Tc-99m Pentetate	Tc-99m Pentetate	NYU Langone Health	marketed	Radiopharmaceutical diagnostic agent
Tc 99m filtered sulfur colloid	Tc 99m filtered sulfur colloid	Memorial Health University Medical Center	marketed	Radiopharmaceutical diagnostic agent
Radium-223	radium-223	Pfizer	marketed	Radiopharmaceutical	Bone cells
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; PET imaging agent class)

1. Clarity Pharmaceuticals Ltd · 1 drug in this class
2. Radiomedix, Inc. · 1 drug in this class
3. Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
4. UMC Utrecht · 1 drug in this class
5. University of Colorado, Denver · 1 drug in this class
6. University of Saskatchewan · 1 drug in this class